Expectations trend
FY2028 · fiscal year ending 2028-08-31 · fmp
LEXARIA BIOSCIENCE CORP (LEXX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.17+2.46%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LEXX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sufficient capital to avoid delisting and fund operations | The company recently raised capital to support operations despite losses. | Under Pressure | Company fails to maintain listing compliance or runs out of cash | Nasdaq delisting notice received vs listing compliance target Nasdaq delisting notification received Aug 4, 2026; 1-for-15 reverse split executed July 29, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-08-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 25, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative development-stage business, not an established earnings compounder. The long-term thesis is intact in the snapshot, but confidence is medium and the business remains loss-making with high risk.
The valuation model shows LEXX at a premium to peers, while its confidence is low and the expectations gap is driven by optionality, meaning value depends on possible future outcomes. The snapshot labels the pricing unjustified, though it does not show the full combination of expensive valuation, weak fundamentals, and turbulence.
Near term, losses and funding needs remain central: third-quarter net income was negative, and management expects about $5.9 million from warrant exercises to support 2027 operations and research. The DehydraTECH platform remains under development, with no revenue growth reported; a recent reverse stock split was completed to address Nasdaq’s minimum-bid rule after a delisting notice. Near-term earnings risk is elevated, although recent financial performance is described as holding in the top half of its industry.
Over the multi-year view, the key question is whether DehydraTECH development can lead to revenue growth while the company secures enough capital to fund operations and research. Near term, weakening jobs data could increase pressure on cyclical names, while continued strength or weakness among Healthcare bellwethers could either support or erode the sector tailwind.
The 1-to-3-year thesis remains intact but speculative, with platform progress and financing execution carrying more weight than current earnings. The evidence is limited on commercial progress and leaves substantial near-term risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in LEXARIA BIOSCIENCE CORP's published investment case. The stated target is EPS >= -$0.31 in FY27. |
| Broken |
| EPS loss worsens beyond -$0.31 in FY27 |
Diluted EPS: $-0.08 per share FY2026-Q3; GAAP. Published target: EPS >= -$0.31 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Jul 13, 2026-0.08 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth recovers to positive by next fiscal year | The market expects revenue to shrink 26% next year, but implied growth over 3 to 5 years is 12.7% to 22.1%. | Broken | Revenue fails to reach $1.4M in FY27 | Revenue: $0 FY2026-Q3; GAAP. Published target: >= $1.4M revenue in FY27. Annual target cannot be compared with a quarterly or TTM observation. Jul 13, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.20 → $-4.20 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-01 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-02 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-03 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-04 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-05 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-06 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-07 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-08 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-09 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-10 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-11 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-12 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-13 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-14 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-15 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-16 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-17 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-18 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-19 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-20 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-21 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-22 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-23 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-24 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-25 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-26 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-27 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-28 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-29 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-09-30 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-01 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-02 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-03 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-04 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-05 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-06 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-07 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-08 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-09 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-10 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-11 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-12 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-13 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-14 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-15 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-16 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-17 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-18 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-19 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-20 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-21 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-22 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-23 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-24 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-25 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-26 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-27 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-28 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-29 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-30 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-10-31 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-11-01 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-11-02 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-11-03 | $-4.20 | $1,585,000 | 1 / 1 |
| 2026-11-04 | $-4.20 | $1,585,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.